[1] 王小时, 郑法雷, 刘燕萍. 慢性肾衰的心血管病变[M]//郑法雷, 章友康, 陈香美, 等主编. 肾脏病临床与进展. 北京:人民军医出版社, 2005:278-287. [2] Shutov AM, Kondrat'eva NI, Kulikova ES, et al. Heart remodeling. In patients with predialysis phase of chronic renal failure[J]. Ter Arkh, 2000, 72(6): 46-49. [3] London GM. Cardiovascular disease in chronic renal failure: pathophysiologic aspects[J]. Semin Dial, 2003, 16 (2): 85-94. [4] Zolk O, Quattek J, Seeland U, et al. Activation of the cardiac endothelin system in left ventricular hypertrophy before onset of heart failure in TG(mREN2) 27 rats[J]. Cardiovasc Res, 2002, 53(2): 363-371. [5] Ram CV. Possible therapeutic role of endothelin antagonists in cardiovasculardisease[J]. Am J Therapeutics, 2003, l0(6): 396-400. [6] 秦旭平, 龙光, 徐立朋, 等. 氯沙坦和培哚普利逆转高血压大鼠心血管重构的比较[J]. 中国药理学通报, 2004, 20(10): 1107-1111. [7] 王迎新, 李远思, 陈燕, 等. 福辛普利与氯沙坦对试验性糖尿病大鼠肾病的防治作用与转化因子β1的关系[J]. 中国药理学通报, 2005, 21(7): 884-888. [8] Piuhola J, Szokodi I, Kinnunen P, et al. Endothelin-1 contributes to the Frank-Starling response in hypertrophic rat hearts[J]. Hypertension, 2003, 41(1): 93-98. [9] Schmieder RE. Endothelial dysfunction:how Can one intervene at the beginning of the cardiovascular continuum[J] ? J Hypertens Suppl, 2006, 24(2): S31-35. [10] Nakamura K, Yamagishi S, Nakamura Y, et al. Telmisartan inhibitsexpression of a receptor for advanced glycation end products(RAGE) in anglotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension[J]. Microvasc Res, 2005, 70 (3): 137-141. [11] Baba T, Kanda T, Kobay ashi I. Reduction of cardiac endothelin-1 by angiotensin II type 1 receptor antagonist in viral myocarditis of mice[J]. Life Sci, 2000, 67(5): 587-597. [12] Naruse M, Tanabe A, Hara Y, et al. Effects of AT1 Receptor Antagonist and Spironolactone on Cardiac Expression of ET-1 mRNA in SHR-SP/Izm[J]. J Cardiovasc Pharmacol, 2004, 44: S1-S3. |